glp1 journey and tirzepatide dosage Dose-equivalence reference based on pivotal GLP-1/dual-agonist trials: SURMOUNT-1 (tirzepatide/Zepbound, 72 weeks) STEP-1 (subcutaneous semaglutide/Wegovy, 68 weeks) OASIS-4 (oral semaglutide/Wegovy, 64 weeks). For educational comparison only—these are Switching Between Semaglutide and Tirzepatide:

In conclusion, maternal HMSeBA supplementation might alleviate ROS induced intestinal ER stress by improving the expression of SELS and GPX4 in their offspring

PF-06882961 agonist activity was assessed at both the cAMP and Arr pathways and compared to the marketed GLP-1R agonists exenatide and liraglutide

Patients receive guidance on proper injection technique, storage in appropriate refrigeration, and recognition of any signs of contamination or degradation

Beginning July 1, 2026, the Centers for Medicare & Medicaid Services (CMS) will launch the Medicare GLP-1 Bridge Program, a temporary demonstration designed to provide eligible Medicare Part D beneficiaries with access to certain GLP-1 medications through December 31, 2027

Weekly weighing prevents getting discouraged by daily fluctuations while providing enough data points to identify trends